Evaluation of novel diagnostic tools for peste des petits ruminants virus in naturally infected goat herds.

A survey was carried out in two goat herds during a single peste des petits ruminant (PPR) outbreak. Clinical examination showed that animals belonging to the West African Dwarf species had severe symptoms while those belonging to the West African long-legged species had mild symptoms. To confirm and to monitor the disease in each species, the study required specific monoclonal antibody-based diagnostic tools. An association of shedding of PPR virus (PPRV) and acute or mild clinical signs of the disease could be demonstrated by the rinderpest virus (RPV)/PPRV immunocapture ELISA assay. Between 85 and 100% of nasal secretions obtained from clinically diseased goats during the PPR outbreak reacted positively. Parallel serological surveillance for specific measurement of PPR antibodies revealed that between 34.4 and 88.5% of animals with no detectable virus were, however, able to seroconvert and therefore seemed to demonstrate that PPR subclinical infections do occur. Antibodies were shown to impair the RP heterologous vaccination. This evaluation offers new prospects for diagnosis and management of PPRV infection as well as for RPV control.

Inexpensive vaccines and rapid diagnostic kits tailor-made for the global eradication of rinderpest, and technology transfer to Africa and Asia.

Rinderpest is an acute and highly contagious viral disease of ruminants, often resulting in greater than 90% mortality. We previously reported the development of first- and second-generation recombinant vaccinia virus vaccines which provide complete protection against rinderpest virus (RPV) and peste-des-petits ruminants virus (PPRV). These vaccines are safe even for immunodeficient mice and macaques with acquired immunodeficiency syndrome. We developed a third-generation recombinant vaccinia virus vaccine (v2RVFH) that expresses the fusion and haemagglutinin genes of RPV under strong synthetic vaccinia virus promoters. Cattle vaccinated intramuscularly with as little as 10(3) plaque-forming units (PFU) of v2RVFH were completely protected from rinderpest. Vaccinated animals did not develop pock lesions or transmit v2RVFH to contact animals. Cattle vaccinated with a standard dose of 10(8) PFU of v2RVFH developed long-term, sterilizing immunity against rinderpest. Thus, v2RVFH is safe, efficacious, heat stable, inexpensive, easily administered, and allows serological differentiation between vaccinated and infected animals. To aid in diagnosis and differentiation of vaccinated from infected animals, we developed indirect ELISAs (iELISAs) that use baculovirus-expressed RPV or PPRV nucleoprotein as coating antigens. A single larva contains enough viral antigen to test more than 10,000 serum samples, in duplicate. African scientists trained at the ILMB successfully transferred the iELISA kit technology to more than 30 countries in Africa, providing a model for technology transfer among developing countries. Vaccination with v2RVFH, in conjunction with the iELISA kits, greatly enhances the prospects for global eradication of rinderpest, as developing nations achieve independence in control efforts.

[Epidemiology of the main respiratory viruses in small ruminants in Mali]. / Epidémiologie des principaux virus à tropisme respiratoire chez les petits ruminants au Mali.

From 1986 to 1988 a sero-epidemiological survey was carried out in Mali by ILCA to identify the small ruminant main respiratory viruses. The results of this investigation shows an endemic condition. Regardless of the virus species involved, neutralizing antibodies were detected in adults as well as in young stocks. New researches are necessary to set forth a consistent and effective policy of prophylaxis or treatment according to the case concerned.